Upadacitinib for the Treatment of Atopic Dermatitis

Emma Guttman-Yassky, MD, sits down with Dermatology Times® to discuss recently published results of a phase 3 study evaluating upadacitinib (Rinvoq, AbbVie) as a potential treatment of atopic dermatitis.

Related Videos
Related Content

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

March 22nd 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

March 22nd 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

March 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.